Page last updated: 2024-08-21

arsenic trioxide and imatinib mesylate

arsenic trioxide has been researched along with imatinib mesylate in 37 studies

Research

Studies (37)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (64.86)	29.6817
2010's	13 (35.14)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Scheinberg, DA	1
Bhalla, KN; Nguyen, D; Nimmanapalli, R; Perkins, C; Porosnicu, M; Worthington, E	1
O'Dwyer, M	1
Bhalla, KN; Druker, BJ; La Rosée, P; Nimmanapalli, R; O'Dwyer, ME	1
Druker, BJ; Johnson, K; La Rosée, P; O'Dwyer, ME	1
Stull, DM	1
Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S	1
Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M	1
Chen, L; Fei, XH; Gao, L; Huang, ZX; Lou, JW; Wang, JM; Xu, XP	1
Kaplow, R	1
Chen, SJ; Zhao, WW	1
Huang, Q	1
Auffray, C; Chen, S; Chen, Y; Chen, Z; Du, Y; Eveno, E; Fan, H; Fang, H; Graudens, E; Imbeaud, S; Li, J; Pan, X; Wang, K; Xiao, D; Zhang, J; Zhang, Q; Zhao, C; Zheng, P	1
Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D	1
Alkharfy, KM; Arafah, MM; Saad, SY	1
Pu, Q	1
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B	1
Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B	1
Chen, GQ; Wang, LS; Wu, YL; Yu, Y	1
Chen, SJ; Chen, Z; Li, G; Zhou, GB	1
Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS	1
Chuah, C; Melo, JV	1
Fang, H; Wang, K; Zhang, J	1
Chen, LJ; Li, XF; Lu, RZ; Ma, J; Qiu, L; Wang, XD; Wang, XL; Zhang, BL	1
Kashimura, M; Ohyashiki, K	1
Chen, NY; Wang, J; Wang, XM; Wang, YM; Yan, B; Yan, ZY; Zhang, HX; Zhang, S	1
Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X	1
Jia, B; Li, JH; Li, XF; Liu, QJ; Ma, J; Qiu, L; Wang, CH; Wang, XL; Xu, W	1
Balayssac, S; Ballot, C; Briand, G; Dammak, A; Dauphin, V; Formstecher, P; Idziorek, T; Jendoubi, M; Joha, S; Jonneaux, A; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Quesnel, B	1
He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L	1
Du, Y; Fang, H; Xia, Y; Zhang, J	1
Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS	1
Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X	1
Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS	1
Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q	1
Bardsley, MR; Burgoyne, AM; Chan, JC; Chmielecki, J; Gao, F; Harismendy, O; Kendrick, ML; Lee, TE; Leonard, SY; Mao, J; Morosini, D; Ordog, T; Ross, JS; Shi, E; Sicklick, JK; Siena, M; Syed, SA; Tang, CM; Wang, K	1
Bazarbachi, A; El Eit, R; Itani, AR; Jabbour, M; Mahon, FX; Nasr, R; Nassar, F; Rasbieh, N; Santina, A; Zaatari, G	1

Reviews

11 review(s) available for arsenic trioxide and imatinib mesylate

Article	Year
Old, new drugs and new, new drugs for the new millennium. Current oncology reports, 2000, Volume: 2, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome	2000
Multifaceted approach to the treatment of bcr-abl-positive leukemias. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome	2002
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002
Targeted therapies for the treatment of leukemia. Seminars in oncology nursing, 2003, Volume: 19, Issue:2 Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin	2003
Investigational strategies in chronic myelogenous leukemia. Hematology/oncology clinics of North America, 2004, Volume: 18, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome	2004
Innovations in antineoplastic therapy. The Nursing clinics of North America, 2005, Volume: 40, Issue:1 Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate	2005
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Current pharmaceutical design, 2006, Volume: 12, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide	2006
Leukemia, an effective model for chemical biology and target therapy. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin	2007
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin	2007
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology. American Society of Hematology. Education Program, 2008 Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2008
Transcriptome and proteome analyses of drug interactions with natural products. Current drug metabolism, 2008, Volume: 9, Issue:10 Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin	2008

Other Studies

26 other study(ies) available for arsenic trioxide and imatinib mesylate

Article	Year
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia, 2001, Volume: 15, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Drug Synergism; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Leukemia; Macrophage-1 Antigen; Oxides; Piperazines; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2001
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental hematology, 2002, Volume: 30, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Biomarkers, Tumor; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood, 2004, Jan-01, Volume: 103, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
[Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Genes, abl; Genes, MDR; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vincristine	2004
[Arsenic treatment for leukemia: new model of human cancer target treatment]. Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin	2005
Chronic myelogenous leukemia in accelerated phase. Archives of pathology & laboratory medicine, 2005, Volume: 129, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2005
Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood, 2006, Feb-15, Volume: 107, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Endoplasmic Reticulum; Growth Inhibitors; Humans; Imatinib Mesylate; K562 Cells; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2006
Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. The Journal of pharmacy and pharmacology, 2006, Volume: 58, Issue:4 Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Combinations; Imatinib Mesylate; Liver; Male; Myocardium; Oxides; Piperazines; Pyrimidines; Rats; Rats, Wistar	2006
[Further improving the standard of treatment for chronic myeloid leukemia]. Zhonghua nei ke za zhi, 2006, Volume: 45, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha	2006
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine	2006
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Haematologica, 2007, Volume: 92, Issue:6 Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines	2007
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:11 Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured	2007
[Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Nuclear Proteins; Oxides; Piperazines; Pyrimidines	2009
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic	2010
[Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells]. Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Caspase 3; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Oxides; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines	2010
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Leukemia research, 2011, Volume: 35, Issue:10 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2011
[Apoptosis of KBM5R cell line with T315I point mutation induced by arsenic trioxide]. Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Oxides; Piperazines; Point Mutation; Pyrimidines	2011
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PloS one, 2011, Volume: 6, Issue:7 Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Cell Death; Cell Line, Tumor; Cell Respiration; Drug Resistance, Neoplasm; Electron Transport; Energy Metabolism; Glucose; Imatinib Mesylate; Isothiocyanates; Leukemia; Mice; Mitochondria; Models, Biological; Oxidative Stress; Oxides; Piperazines; Pyrimidines; Reactive Oxygen Species	2011
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results. Leukemia & lymphoma, 2014, Volume: 55, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin	2014
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Experimental biology and medicine (Maywood, N.J.), 2013, Aug-01, Volume: 238, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome	2013
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. International journal of cancer, 2014, Feb-15, Volume: 134, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay	2014
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:6 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligodeoxyribonucleotides, Antisense; Oxides; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2013
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. Oncogene, 2014, Nov-13, Volume: 33, Issue:46 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2014
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms. Molecular medicine reports, 2014, Volume: 10, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger	2014
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Line, Tumor; Cell Survival; Cilia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mutation; Nerve Tissue Proteins; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3	2016
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Cancer, 2019, 08-15, Volume: 125, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors	2019